02:14 PM EDT, 06/28/2024 (MT Newswires) -- Morgan Stanley halved Accolade's (ACCD) price target to $6 from $12 while keeping its equal-weight stock rating.

Truist adjusted its price objective to $9 from $14 but maintained the buy rating.

Late Thursday Accolade reported narrower-than-expected fiscal Q1 loss and higher-than-forecast sales. Its guidance for Q2 and full-year sales missed the average analyst estimates compiled by Capital IQ.

Shares sank 42.6%, with intraday trading volume at more than 9.9 million versus a daily average of about 724,000.

Nexalin Technology ( NXL ) shares sank 39% amid heavy trading after the company said overnight that it priced a public offering of 3 million shares at $1.75 apiece, for gross proceeds of roughly $5.3 million.

More than 3.87 million shares traded intraday compared with a daily average of about 2.87 million.

Wedbush Securities cut Nike's ( NKE ) price target to $97 from $115 while maintaining its outperform rating after "very choppy" fiscal Q4 earnings.

Shares dropped more than 20% as intraday trading volume soared to over 96.4 million versus a daily average of about 9.21 million.

Price: 3.67, Change: -2.72, Percent Change: -42.58